Search Results
Your search for ,iII matches 9601 pages
Showing 2501 - 2550100% Complete Response Rate in 14 Patients With Rectal Cancer Treated With Neoadjuvant Dostarlimab-gxly
In a study of 18 patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of neoadjuvant treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses in 100% of the study’s first 14 patients.1 These results were presented at the 2022...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
CheckMate 274: Adjuvant Immunotherapy Improves Disease-Free Survival in Metastatic Urothelial Cancer
Adjuvant nivolumab could become the standard of care for patients with metastatic bladder cancer, according to data presented at the American Urological Association (AUA) 2022 Annual Meeting.1 With longer follow-up, the results of the phase III CheckMate 274 trial showed that treatment with the...
Ovarian Cancer: First-Line Every-3-Week Carboplatin/Paclitaxel vs Weekly Dose-Dense Regimens
As reported in The Lancet Oncology by Andrew R. Clamp, PhD, and colleagues, no significant differences in overall survival or updated progression-free survival were found with first-line treatment with weekly dose-dense regimens of carboplatin/paclitaxel vs every-3-week carboplatin/paclitaxel in...
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer in Persons With HIV
In the phase III ANCHOR study reported in The New England Journal of Medicine, Palefsky et al found that treatment of high-grade squamous intraepithelial lesions was successful in preventing anal cancer vs active monitoring in persons infected with HIV. Study Details In the multicenter trial, 4,446 ...
Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide
Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used...
Rainer Fietkau, MD, on Pancreatic Cancer: Initial Trial Results on Sequential Chemotherapy and Chemoradiotherapy
Rainer Fietkau, MD, of Germany’s University Hospital Erlangen, discusses phase III findings of the CONKO-007 trial, which examined the role of sequential chemotherapy and chemoradiotherapy administered to patients with nonresectable locally advanced pancreatic cancer following standard-of-care...
Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients
Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without...
An Oncology Surgeon Leads Mexico’s Melanoma Program
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with surgical oncologist Héctor Martínez-Said, MD, of the Melanoma Clinic at NCI Mexico. Dr. Martínez-Said’s maternal grandfather was part of a Lebanese immigration movement...
Overall Survival in Patients With Metastatic Colorectal Cancer in Phase III Trials and SEER Database Over a 30-Year Period
In a study reported in JAMA Network Open, Shen et al found that data from both phase III trials and the Surveillance, Epidemiology, and End Results (SEER) database indicate significant improvements in overall survival for patients with metastatic colorectal cancer over a 30-year period. Increases...
Erika Hamilton, MD, on Metastatic Breast Cancer: Safety Follow-up Data on T-DXd vs T-DM1
Erika Hamilton, MD, of Sarah Cannon Research Institute at Tennessee Oncology, discusses phase III data from the DESTINY-Breast03 study, which reinforced the consistent safety profile of fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...
Eunice S. Wang, MD, on AML: Long-Term Results With Crenolanib Plus Chemotherapy
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses long-term phase II findings of a trial evaluating crenolanib plus chemotherapy in newly diagnosed adults with FLT3-mutant acute myeloid leukemia. The study showed a composite complete remission rate of 86%. With a median...
Androgen Receptor Signaling May Contribute to Targeted Therapy Resistance in Patients With Melanoma
Androgen receptor (AR) signaling may affect response to BRAF/MEK inhibitor therapy in both male and female patients with melanoma, according to findings from a study published by Vellano et al in Nature. The report provides a new target to combat therapeutic resistance and one possible answer to...
Can Abemaciclib Provide Good Clinical Outcomes in Patients With High-Risk Hormone Receptor–Positive, HER2-Negative Breast Cancer Who Received Neoadjuvant Chemotherapy?
In a prespecified analysis from the phase III monarchE trial reported in JAMA Oncology, Miguel Martín, MD, PhD, and colleagues found that the addition of adjuvant abemaciclib to endocrine therapy was associated with improved outcomes among women with high-risk hormone receptor–positive,...
Proposed Second Revision of the International Staging System for Survival in Multiple Myeloma
As reported in the Journal of Clinical Oncology by D’Agostino et al in the European Myeloma Network, a second revision (R2-ISS) of the Revised International Staging System (R-ISS) incorporates a risk scoring system that permits delineation of four prognostic risk groups in newly diagnosed multiple...
Risk of Skin Desquamation With Breast Radiotherapy: Does Position Change Outcomes in Large-Breasted Women?
In a Canadian phase III trial reported in JAMA Oncology, Vesprini et al found that receipt of adjuvant breast radiotherapy in the supine position was associated with increased risk of moist desquamation of skin vs receipt in the prone position among large-breasted women with breast cancer. Study...
Magrolimab Plus Azacitidine in TP53-Mutant AML
High-risk patients with TP53-mutated acute myeloid leukemia (AML) have limited treatment options and very poor prognoses. Magrolimab is a monoclonal antibody designed to block CD47, an immune macrophage checkpoint molecule that signals “don’t eat me,” thereby allowing leukemia cell destruction....
Intracranial Efficacy of Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
In a post hoc analysis from the phase III CROWN trial reported in the Journal of Clinical Oncology, Benjamin J. Solomon, MBBS, PhD, and colleagues found that progression-free survival and the risk of central nervous system (CNS) progression were improved with lorlatinib vs crizotinib in previously...
Metformin vs Placebo in Patients With High-Risk Operable Breast Cancer Receiving Standard Treatment
As reported in JAMA by Pamela J. Goodwin, MD, MSc, FRCPC, FASCO, the phase III MA.32 trial showed no invasive disease–free survival benefit with metformin vs placebo in patients without diabetes receiving standard therapy for high-risk nonmetastatic breast cancer. Study Details In the double-blind ...
Lisa A. Carey, MD, and Shanu Modi, MD, on Breast Cancer: Is T-DXd a Potential New Standard of Care for HER2-Low Disease?
Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discuss the phase III findings from the DESTINY-Breast04 trial, which compared fam-trastuzumab deruxtecan-nxki (T-DXd) vs treatment of...
Andrew D. Zelenetz, MD, PhD, and Michael L. Wang, MD, on Mantle Cell Lymphoma: New Data on Ibrutinib in Combination With Bendamustine/Rituximab and Rituximab Maintenance
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Michael L. Wang, MD, of The University of Texas MD Anderson Cancer Center, discuss primary results from the phase III SHINE study, which showed that ibrutinib, in combination with bendamustine/rituximab and rituximab...
Ursula A. Matulonis, MD, and Domenica Lorusso, MD, PhD, on Gynecologic Cancers: New Findings on Trabectedin vs Clinician’s Choice Chemotherapy
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Domenica Lorusso, MD, PhD, of Italy’s Gemelli University Hospital, discuss phase III data from the MITO23 trial on single-agent trabectedin vs clinician’s choice of chemotherapy in patients with recurrent ovarian, primary peritoneal, or...
Personalized ctDNA Testing and Late Recurrence in High-Risk HR-Positive, HER2-Negative Breast Cancer
In a study presented at the 2022 ASCO Annual Meeting (Abstract 103) and simultaneously reported in the Journal of Clinical Oncology, Lipsyc-Sharf et al found that personalized circulating tumor DNA (ctDNA) testing was successful in detecting measurable residual disease (MRD) prior to late clinical...
Robotic Surgery Improves Perioperative Outcomes vs Open Radical Cystectomy in Bladder Cancer Trial
Patients who underwent robotic-assisted radical cystectomy with intracorporeal diversion spent fewer days in the hospital and experienced fewer complications compared with those who underwent open radical cystectomy, according to data presented at the 2022 American Urological Association (AUA)...
Use of T-DXd in Previously Treated Patients With Advanced HER2-Positive Breast Cancer
On May 4, 2022, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted regular approval for patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed...
Cemiplimab-rwlc Following Platinum-Based Chemotherapy in Recurrent or Metastatic Cervical Cancer: Clinical Implications
It is estimated that globally, more than 600,000 women per year are diagnosed with cervical cancer, and more than 300,000 die annually of the disease.1 Many women continue to be diagnosed with cervical cancer at an advanced stage, with a high risk of recurrence. To date, the most effective...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Expert Point of View: Mafalda Oliveira, MD, PhD
Invited discussant of the MONALEESA-3 trial, Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, commented: “I totally agree with the authors when they say these results are ‘impressive.’” Among all the phase III trials evaluating...
DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?
Since the introduction of trastuzumab in the late 1990s, overall survival for patients with HER2-positive metastatic breast cancer has substantially improved. Median overall survival in the pivotal first-line trial was only 20.3 months in the chemotherapy arm, and 25.1 months in the...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
T-DXd Improves Progression-Free Survival vs T-DM1 in Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, of the International Breast Cancer Center, Barcelona, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs...
Momelotinib for Symptomatic and Anemic Patients With Myelofibrosis
Once-daily treatment with the oral JAK1/2 and ACVR1/ALK2 inhibitor momelotinib significantly improved outcomes of patients treated for myelofibrosis. Ruben Mesa, MD, FACP, and colleagues presented results of the MOMENTUM phase III randomized study, which evaluated momelotinib vs danazol in...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 Trial
In an analysis presented at the 2022 ASCO Annual Meeting (Abstract 8028) and simultaneously reported in the Journal of Clinical Oncology, Thomas Martin, MD, and colleagues provided data from the 2-year follow-up of the pivotal CARTITUDE-1 trial of the anti–B-cell maturation agent (BCMA) chimeric...
Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Renal Cell Carcinoma: New Data on Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, discuss phase III findings from the KEYNOTE-426 trial, which appear to support the long-term benefit of pembrolizumab plus axitinib for...
Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Long-Term Outcomes With Enfortumab Vedotin-ejfv vs Chemotherapy
Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss the 24-month findings from the phase III EV-301 trial, which suggest that enfortumab vedotin-ejfv continues to show a significant and ...
FLT3 Inhibitor Crenolanib in Combination With Chemotherapy for Newly Diagnosed Patients With FLT3-Mutant AML
Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, and colleagues presented the long-term results of a phase II clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for the treatment of adults with newly diagnosed ...
mFOLFOXIRI/Panitumumab vs mFOLFOX/Panitumumab for the Initial Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer
In an Italian phase III trial (TRIPLETE) presented at the 2022 ASCO Annual Meeting (Abstract LBA3505) and simultaneously published in the Journal of Clinical Oncology, Rossini et al found that mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus panitumumab did not...
ATHENA-MONO Trial: Rucaparib Maintenance in Newly Diagnosed Patients With Advanced Ovarian Cancer
As presented at the 2022 ASCO Annual Meeting (Abstract LBA5500) and simultaneously reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III ATHENA-MONO trial found that maintenance rucaparib significantly improved progression-free survival vs placebo among...
Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy
Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able to avoid radiation therapy entirely, according to new research findings presented by Timothy Joseph ...
Georgina V. Long, MD, PhD, on Melanoma: Distant Metastasis–Free Survival With Adjuvant Pembrolizumab
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses phase III findings from the KEYNOTE-716 study. The trial showed that compared with placebo, adjuvant pembrolizumab significantly improved distant metastasis–free survival in patients with resected...
Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib
Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had...
Georgina V. Long, MD, PhD, on Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, The University of Sydney, discusses findings from the NeoTrio trial on neoadjuvant pembrolizumab alone, in sequence with, or concurrent with dabrafenib plus trametinib in patients with resectable BRAF-mutant stage III melanoma. The...
Courtney D. DiNardo, MD, MSCE, and Stéphane de Botton, MD, PhD, on AML: New Data on IDH2-Mutant Alleles, Enasidenib, and Conventional Care
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Stéphane de Botton, MD, PhD, of Institut Gustave Roussy, discuss phase III findings from the IDHENTIFY trial, which showed that mutational burden and co-mutational profiles differed between patients with...
Carryn M. Anderson, MD, on Head and Neck Cancer: New Data on Avasopasem Manganese for Oral Mucositis
Carryn M. Anderson, MD, of the University of Iowa Hospital, discusses phase III results of the ROMAN trial of avasopasem manganese for patients with severe oral mucositis who are receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck cancer. Compared with placebo, avasopasem...
Stephen M. Ansell, PhD, MD, on Hodgkin Lymphoma: An Updated Analysis on First-Line Brentuximab Vedotin Plus Chemotherapy
Stephen M. Ansell, PhD, MD, of Mayo Clinic, discusses updated data from the ECHELON-1 trial, which showed that, when administered to patients with stage III or IV classical Hodgkin lymphoma, the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin,...
Ursula A. Matulonis, MD, and Nicoletta Colombo, MD, on Ovarian Cancer: Overall Survival Data on Relacorilant Plus Nab-Paclitaxel
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Nicoletta Colombo, MD, of the University of Milan and the European Institute of Oncology, discuss phase II results on the overall survival benefit of intermittent relacorilant, a selective glucocorticoid receptor modulator, combined with ...
'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly
Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...
Courtney D. DiNardo, MD, MSCE, and Jorge E. Cortes, MD, on CML: New Efficacy and Safety Results for Asciminib
Courtney D. DiNardo, MD, MSCE, of The University of Texas MD Anderson Cancer Center, and Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discuss phase III results from the ASCEMBL trial, which showed that after more than 2 years of follow-up, asciminib continued to yield...
Lisa A. Carey, MD, and Hope S. Rugo, MD, on Advanced Breast Cancer: New Data on Sacituzumab Govitecan-hziy vs Treatment of Physician’s Choice
Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss phase III results from the TROPiCS-02 trial. This study showed that...
Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination...
